Patents Represented by Attorney Scott A. Whitaker
-
Patent number: 8143236Abstract: Compositions and methods for reducing, preventing, mitigating, and/or delaying the onset of, attenuating the severity of, and/or hastening the resolution of, for example, one or more chemotherapy-associated toxicities in a subject receiving one or more chemotherapeutic agents. In addition compositions and methods for mitigating or preventing a novel form of chemotherapy-induced peripheral neuropathy are disclosed and claimed.Type: GrantFiled: March 14, 2008Date of Patent: March 27, 2012Assignee: BioNumerik Pharmaceuticals, Inc.Inventor: Frederick H. Hausheer
-
Patent number: 8026227Abstract: Compositions and methods for reducing, preventing, mitigating, and/or delaying the onset of, attenuating the severity of, and/or hastening the resolution of, for example, one or more chemotherapy-associated toxicities in a subject receiving one or more chemotherapeutic agents.Type: GrantFiled: December 13, 2006Date of Patent: September 27, 2011Assignee: BioNumerik Pharmaceuticals, Inc.Inventor: Frederick H. Hausheer
-
Patent number: 7829541Abstract: Novel compositions and formulations are disclosed that have use as toxicity-reducing agents for various chemotherapeutic agents and as treatment for certain diseases and conditions. The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium.Type: GrantFiled: November 14, 2007Date of Patent: November 9, 2010Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Harry Kochat, Qiuli Huang
-
Patent number: 7829540Abstract: Novel compositions and formulations are disclosed that have use as toxicity-reducing agents for various chemotherapeutic agents and as treatment for certain diseases and conditions. The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium.Type: GrantFiled: November 14, 2007Date of Patent: November 9, 2010Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Harry Kochat, Qiuli Huang
-
Patent number: 7829539Abstract: Novel compositions and formulations are disclosed that have use as toxicity-reducing agents for various chemotherapeutic agents and as treatment for certain diseases and conditions. The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium.Type: GrantFiled: November 14, 2007Date of Patent: November 9, 2010Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Harry Kochat, Qiuli Huang
-
Patent number: 7829538Abstract: Novel compositions and formulations are disclosed that have use as toxicity-reducing agents for various chemotherapeutic agents and as treatment for certain diseases and conditions. The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium.Type: GrantFiled: November 14, 2007Date of Patent: November 9, 2010Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Harry Kochat, Qiuli Huang
-
Patent number: 7829117Abstract: Novel compositions and formulations are disclosed that have use as toxicity-reducing agents for various chemotherapeutic agents and as treatment for certain diseases and conditions. The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium.Type: GrantFiled: November 14, 2007Date of Patent: November 9, 2010Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Harry Kochat, Qiuli Huang
-
Patent number: 7777060Abstract: Disclosed herein are novel platinum-based analogs possessing two nitrile substituent groups (bis-nitrile) covalently-bonded to the platinum. Also disclosed herein are the reaction schemes for the synthesis of said platinum complexes, as well as quantitative in vitro IC50 data.Type: GrantFiled: October 30, 2007Date of Patent: August 17, 2010Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Xinghai Chen, Pavankumar N. V. Petluru, Qiuli Huang, Kesavaram Narkunan, Frederick Hausheer
-
Patent number: 7759488Abstract: Disclosed herein are novel platinum-based analogs with a single substituted azole ligand: RN?NR7, wherein the RN?NR7 functional group is covalently bonded to the platinum through nitrogen of NR7. The analogs also have nitrogen donor ligands capable of forming hydrogen bonds with the bases in DNA or RNA, and one or more leaving groups which can be displaced by water, hydroxide ions or other nucleophiles, which is thought to form active species in vivo, and then, form cross-linked complexes between nucleic acid strands, principally between purines in DNA (or RNA), i.e., at the Guanine or Adenine bases, thereof.Type: GrantFiled: January 26, 2006Date of Patent: July 20, 2010Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Zejun Xiao, Harry Kochat, Frederick H. Hausheer
-
Patent number: 7687497Abstract: The novel C10-modified camptothecin analogs, and pharmaceutically-acceptable salts thereof, of the present invention: (i) possess potent antitumor activity (i.e., in nanomolar or subnanomolar concentrations) for inhibiting the growth of human and animal tumor cells in vitro; (ii) are potent inhibition of Topoisomerase I; (iii) lack of susceptibility to MDR/MRP drug resistance; (iv) require no metabolic drug activation: (v) lack glucuronidation of the A-ring or B-ring; (vi) reduce drug-binding affinity to plasma proteins; (vii) maintain lactone stability; (viii) maintain drug potency; and (ix) possess a low molecular weight (e.g., MW<600).Type: GrantFiled: October 16, 2007Date of Patent: March 30, 2010Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Kesavaram Narkunan, Xinghai Chen, Harry Kochat, Frederick Hausheer
-
Patent number: 7687496Abstract: The novel C7-modified camptothecin analogs, and pharmaceutically-acceptable salts thereof, of the present invention: (i) possess potent antitumor activity (i.e., in nanomolar or subnanomolar concentrations) for inhibiting the growth of human and animal tumor cells in vitro; (ii) are potent inhibition of Topoisomerase I; (iii) lack of susceptibility to MDR/MRP drug resistance; (iv) require no metabolic drug activation: (v) lack glucuronidation of the A-ring or B-ring; (vi) reduce drug-binding affinity to plasma proteins; (vii) maintain lactone stability; (viii) maintain drug potency; and (ix) possess a low molecular weight (e.g., MW<600).Type: GrantFiled: October 16, 2007Date of Patent: March 30, 2010Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Kesavaram Narkunan, Xinghai Chen, Harry Kochat, Frederick Hausheer
-
Patent number: 7687487Abstract: The present invention discloses: (i) a novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof; (ii) methods of synthesis of said novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof; (iii) pharmaceutically-acceptable formulations comprising said novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one or more additional chemotherapeutic agents; (iv) methods of administration of said novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one or more additional chemotherapeutic agents, to subjects in need thereof; and (v) devices for the administration of said novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one or more chemotherapeutic agents, to subjects in need therType: GrantFiled: April 19, 2007Date of Patent: March 30, 2010Assignee: BioNumerik Pharmaceuticals, Inc.Inventor: Frederick H. Hausheer
-
Patent number: 7268244Abstract: Disclosed herein are novel platinum-based analogs with a single substituted imine ligand: R7RC?NR8, wherein the R7RC?NR8 functional group is covalently bonded to the platinum through nitrogen. The analogs also have nitrogen donor ligands capable of forming hydrogen bonds with the bases in DNA or RNA, and one or more leaving groups which can be displaced by water, hydroxide ions or other nucleophiles, which is thought to form active species in vivo, and then, form cross-linked complexes between nucleic acid strands, principally between purines in DNA (or RNA), i.e., at the Guanine or Adenine bases, thereof.Type: GrantFiled: January 26, 2006Date of Patent: September 11, 2007Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Zejun Xiao, Harry Kochat
-
Patent number: 7238823Abstract: Disclosed herein are novel platinum-based complexes possessing one nitrile substituent group (mononitrile) covalently-bonded to the platinum, one or more nitrogen donor ligands capable of forming hydrogen bonds with the bases in DNA or RNA and leaving groups (i.e., L1 and L2) which can be hydrolyzed in vivo to active species, which can then form coordinate adducts with DNA or RNA at the Guanine or Adenine bases thereof. Also disclosed herein are the reaction schemes for the synthesis of said platinum complexes, as well as methods of treatment of various types of cancer by the administration of a pharmaceutically-effective dose of said novel platinum complexes.Type: GrantFiled: January 26, 2006Date of Patent: July 3, 2007Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Zejun Xiao, Frederick H. Hausheer, Pavankumar Petluru